Cardiovascular diseases (CVDs) are among the leading causes of death worldwide.
Traditional treatment options such as pharmacological interventions and surgical procedures
often do not fully address the underlying issue of heart tissue damage and loss of function. In
recent years, advancements in regenerative medicine, particularly stem cell therapy and gene
editing technologies, have shown promising potential to revolutionize heart regeneration.
This paper explores the current state of stem cell-based therapies and gene editing techniques,
such as CRISPR-Cas9, in the context of cardiovascular medicine. It discusses their
mechanisms, clinical applications, challenges, and potential future developments in the field.
While these technologies offer hope for patients suffering from heart diseases, several
technical, ethical, and regulatory challenges remain that must be addressed to realize their full
potential.
You may also start an advanced similarity search for this article.